Tracking a Medicine's Regulatory Risk Management Commitments Provides Better Transparency and Oversight

Area of Science:

• Pharmacovigilance and Drug Safety
• Regulatory Affairs
• Health Informatics

Background:

• Pharmaceutical companies require Risk Management Plans (RMPs) for marketing authorisation, detailing efficacy, safety, and post-authorisation pharmacovigilance (PV) commitments.
• RMPs evolve with new data and indications, leading to multiple versions, and may require additional risk minimization materials (aRMMs) for healthcare professionals and patients.
• Implementing RMPs and aRMMs globally involves complex localisation, regulatory approval, dissemination, and effectiveness tracking, posing significant data management challenges.

Purpose of the Study:

• To explore the development and deployment of a database-driven system for tracking Risk Management Plans (RMPs) and additional risk minimization materials (aRMMs).
• To address the critical data management issues arising from managing multiple versions of RMPs and aRMMs and associated global activities.
• To assess the impact of implementing such a system on pharmaceutical organizations.

Main Methods:

• Systematic determination of requirements for a database-driven RMP and aRMM tracking system.
• Development and deployment of the proposed tracking system.
• Assessment of the system's impact on organizational processes and data management.

Main Results:

• The development and implementation of a database-driven system effectively manage multiple RMP and aRMM versions.
• Improved tracking of document status and locally agreed activities across different markets.
• Demonstrated positive impact on organizational efficiency in managing global risk management commitments.

Conclusions:

• A database-driven tracking system is vital for efficiently managing complex RMPs and aRMMs in the pharmaceutical industry.
• The system enhances understanding and control over drug benefit-risk profiles through streamlined pharmacovigilance activities.
• Successful implementation leads to improved regulatory compliance and operational efficiency in global drug safety management.